Barbara Davis Center for Childhood Diabetes

Summary

Barbara Davis Center for Childhood Diabetes is a medical facility located in Aurora, Colorado. This center is recognized for care of Type 1 Diabetes, Diabetes, Hypoglycemia, Type 2 Diabetes, Insulin Resistance and other specialties. Barbara Davis Center for Childhood Diabetes is involved with conducting 113 clinical trials across 40 conditions. There are 12 research doctors associated with this hospital, such as Andrea Steck, MD, Peter Gottlieb, MD, Robert Slover, MD, and Sarit Polsky, MD.

Top PIs

Clinical Trials running at Barbara Davis Center for Childhood Diabetes

Diabetes

Type 1 Diabetes

Anxiety Disorders

Depression

Meal Strategies

for Type 1 Diabetes

The goal of this trial is to evaluate blood sugar control in patients with type 1 diabetes when using a simple meal bolus strategy (small, medium, large meals) compared to carbohydrate counting when on a hybrid closed loop system. The main question it aims to answer are: What is the blood sugar time in range when using simple meal boluses versus carbohydrate counting? Participants will: Use the simple meal bolus plan for 4 weeks. Do precise carbohydrate counting for 4 weeks. Provide their continuous glucose monitor and pump data Take surveys about the experience of meal bolusing during the study

Recruiting

1 award

N/A

1 criteria

CNP-103

for Type 1 Diabetes

This study is a Phase 1b/2a First-in-Human (FIH) clinical trial to assess the safety, tolerability, pharmacodynamics (PD), and efficacy of multiple ascending doses of CNP-103. The approximately 208-day study consists of a Screening Period (28 days), Treatment Period (90 days), and Post-Dose Evaluations (90 days).

Recruiting

0 awards

Phase 1 & 2

ATG + Verapamil

for Type 1 Diabetes

T cell directed therapy, anti-thymocyte globulin (ATG), in low doses, has been shown to lower HbA1c and preserve endogenous insulin production (measured by C-peptide) in individuals with recently diagnosed type 1 diabetes (T1D). However, not all individuals who received ATG responded to the therapy (i.e., non-responders). Additionally, use of ATG alone does not address inherent beta cell stress. A calcium channel blocker, verapamil, has demonstrated C-peptide preservation in newly diagnosed T1D. Investigators will identify those mostly likely to respond to ATG using an ex vivo predictive biomarker of response to ATG. In addition, Investigators will use sequential therapies to increase efficacy (ATG followed by verapamil) and explore synergistic mechanisms. This will be assessing with in depth immunophenotyping and quantify biomarkers of beta cell stress, cell death, and abnormal prohormone processing. Finally, novel clinical trial endpoints will be assessed for their ability to predict treatment efficacy earlier than the standard endpoint at 1 year.

Recruiting

0 awards

Phase 2

3 criteria